Bayer Future Growth

Future criteria checks 3/6

Bayer is forecast to grow earnings and revenue by 37.5% and 1.4% per annum respectively. EPS is expected to grow by 37.7% per annum. Return on equity is forecast to be 12.7% in 3 years.

Key information

37.5%

Earnings growth rate

37.7%

EPS growth rate

Pharmaceuticals earnings growth	18.3%
Revenue growth rate	1.4%
Future return on equity	12.7%
Analyst coverage	Good
Last updated	17 Oct 2024

Recent future growth updates

Bayer Aktiengesellschaft Just Missed Earnings; Here's What Analysts Are Forecasting Now

Aug 09

Recent updates

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

Sep 13

Bayer Aktiengesellschaft Just Missed Earnings; Here's What Analysts Are Forecasting Now

Aug 09

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

Jun 11

The Market Doesn't Like What It Sees From Bayer Aktiengesellschaft's (ETR:BAYN) Revenues Yet

May 07

Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Be 45% Below Their Intrinsic Value Estimate

Aug 05

Is Bayer (ETR:BAYN) A Risky Investment?

Jun 28

Earnings and Revenue Growth Forecasts

XTRA:BAYN - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	48,402	3,370	4,234	7,779	17
12/31/2025	47,755	2,973	4,257	7,857	18
12/31/2024	46,988	2,216	3,260	6,676	18
6/30/2024	47,113	-1,266	5,690	8,443	N/A
3/31/2024	47,013	-3,119	3,786	6,517	N/A
12/31/2023	47,637	-2,941	2,366	5,117	N/A
9/30/2023	47,775	-3,667	-508	2,571	N/A
6/30/2023	48,714	1,448	-473	2,649	N/A
3/31/2023	50,489	3,037	1,203	4,269	N/A
12/31/2022	50,739	4,150	4,144	7,093	N/A
9/30/2022	49,857	4,700	4,313	7,078	N/A
6/30/2022	48,357	4,239	4,547	7,235	N/A
3/31/2022	46,392	2,202	4,497	7,128	N/A
12/31/2021	44,081	1,000	2,478	5,089	N/A
9/30/2021	42,958	222	430	2,794	N/A
6/30/2021	41,683	-7,565	-314	1,950	N/A
3/31/2021	40,883	-14,849	11	2,367	N/A
12/31/2020	41,400	-15,569	2,485	4,903	N/A
9/30/2020	42,155	-15,995	4,805	7,398	N/A
6/30/2020	43,479	-7,303	4,940	7,713	N/A
3/31/2020	44,138	2,631	4,253	6,899	N/A
12/31/2019	43,545	2,391	5,557	8,207	N/A
9/30/2019	43,150	-1,530	5,221	7,929	N/A
6/30/2019	42,581	287	5,060	7,698	N/A
3/31/2019	39,856	557	5,699	8,338	N/A
12/31/2018	36,742	1,374	5,324	7,917	N/A
9/30/2018	34,983	6,027	4,833	7,218	N/A
6/30/2018	33,747	3,237	5,595	7,878	N/A
3/31/2018	34,473	3,486	N/A	7,951	N/A
12/31/2017	35,015	3,249	N/A	8,134	N/A
9/30/2017	35,242	3,087	N/A	8,597	N/A
6/30/2017	35,475	3,924	N/A	8,939	N/A
3/31/2017	32,769	3,991	N/A	8,608	N/A
12/31/2016	34,943	3,743	N/A	9,089	N/A
9/30/2016	37,405	3,837	N/A	8,234	N/A
6/30/2016	40,151	3,971	N/A	7,511	N/A
3/31/2016	46,146	4,210	N/A	7,488	N/A
12/31/2015	46,085	4,025	N/A	6,890	N/A
9/30/2015	45,592	3,616	N/A	7,243	N/A
6/30/2015	44,555	3,429	N/A	6,729	N/A
3/31/2015	42,780	3,206	N/A	6,371	N/A
12/31/2014	41,339	3,326	N/A	5,810	N/A
9/30/2014	40,435	3,569	N/A	5,160	N/A
6/30/2014	40,111	3,501	N/A	5,072	N/A
3/31/2014	40,243	3,425	N/A	5,007	N/A
12/31/2013	40,157	3,189	N/A	5,171	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BAYN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).

Earnings vs Market: BAYN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BAYN is expected to become profitable in the next 3 years.

Revenue vs Market: BAYN's revenue (1.4% per year) is forecast to grow slower than the German market (5.5% per year).

High Growth Revenue: BAYN's revenue (1.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BAYN's Return on Equity is forecast to be low in 3 years time (12.7%).

Bayer Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Bayer Aktiengesellschaft Just Missed Earnings; Here's What Analysts Are Forecasting Now

Price target decreased by 7.7% to €42.48

Price target decreased by 7.7% to €51.57

Price target decreased by 7.6% to €57.57

Consensus EPS estimates increase by 13%

Consensus EPS estimates fall by 11%

Recent updates

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

Bayer to Present Phase III Kerendia (Finerenone) Data

Bayer Aktiengesellschaft Just Missed Earnings; Here's What Analysts Are Forecasting Now

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

The Market Doesn't Like What It Sees From Bayer Aktiengesellschaft's (ETR:BAYN) Revenues Yet

Upcoming dividend of €0.11 per share

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Price target decreased by 7.7% to €42.48

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Dividend of €0.11 announced

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt In A Risky Way

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Are Investors Undervaluing Bayer Aktiengesellschaft (ETR:BAYN) By 42%?

Williams Hart & Boundas Wins Against Bayer

Price target decreased by 7.7% to €51.57

Price target decreased by 7.6% to €57.57

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 13%

Bayer Announces Pharmacodynamic Data on Kerendia

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Bayer (ETR:BAYN) Takes On Some Risk With Its Use Of Debt

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

Consensus EPS estimates fall by 11%

New minor risk - Profit margin trend

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Consensus EPS estimates fall by 12%

Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Be 45% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 24%

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Initiates Phase III Studies with Investigational Compound Agent Gadoquatrane

Is Bayer (ETR:BAYN) A Risky Investment?

FDA Approves Bayer's Ultravist® (iopromide) Injection for contrast-enhanced Mammography

Bayer to Investigate Finerenone in Phase Iii Study in Adults with Chronic Kidney Disease Associated with Type 1 Diabetes

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies